• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Ravi Vij Discusses Benefits/Efficacy of Carfilzomib and Revlimid

Article

Dr. Ravi Vij, Associate Professor of Medicine, Washington University School of Medicine, St. Louis, MO, serves in the Section of Stem Cell Transplant and Leukemia, Division of Oncology. In this interview, he discusses several new molecules headed for FDA approval to treat multiple myeloma.

In addition, Dr. Vij talks about the efficacy of carfilzomib and lenalidomide (Brand name: Revlimid), two drugs seeking accelerated approval by the FDA. He also discusses new molecules in Phase III clinical trials. "This is an exciting time. Outcomes have continued to improve over the past decade for patients with multiple myeloma. However, we have a way to go, as multiple myeloma is still fatal in most patients," said Dr. Vij.

Related Videos
dr monica li
dr lawrence eichenfield
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Will Shapiro, vice president of data science, Flatiron Health
Dr Michael Morse, Duke University
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Ross Margulies, health care attorney and partner at Foley Hoag LLP.
Pat Van Burkleo
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.